1200 gloves for a hospital in Ivory Coast

A Dabou Hospital in Ivory Coast is using 1200 medical gloves donated by atHeart Medical.

1200 gloves for an Ivory Coast hospital

A Dabou Hospital in Ivory Coast is using 1200 medical gloves donated by atHeart Medical.

The ASD closure that started Ella’s best life

Ella suffered from migraine and severe fatigue as a teenager and now has a new…

reSept in Congenital Cardiology Today

The reSept ASD Occluder is featuring in an extensive article by Professor Tom Jones in…

reSept ASD Occluder implanted in EU for the first time

The reSept ASD Occluder has now been implanted in France and EU for the first…

FDA Approved Second Phase of ASCENT ASD

atHeart Medical has received approval for the start of the second phase of its ASCENT…

Mathilda has a special heart

The story of the first patient implanted with a reSept ASD Occluder in Switzerland.

Andrew Cleeland joins atHeart Medical’s Board

atHeart Medical, today announced the appointment of Andrew Cleeland to the company’s Board of Directors.

First Five Patients Successfully Treated

atHeart Medical announced today the successful treatment of the first five patients in its ASCENT…

atHeart Medical has commenced operations

atHeart Medical announced today that it has commenced operations and is initiating its U.S. Investigational…

Beginning with a purpose

I couldn’t be more enthusiastic about our purpose at atHeart Medical: allowing more future options…

February 8, 2022

atHeart Medical Receives FDA Approval for the Second Phase of the ASCENT ASD U.S. IDE Trial

atHeart Medical today announced it has received approval for the start of the second phase of its ASCENT ASD U.S. Investigational Device Exemption (IDE) pivotal trial.

Read more

July 14, 2021

First Five Patients Successfully Treated with reSeptTM ASD Occluder in U.S. IDE Pivotal Trial

atHeart Medical announced today the successful treatment of the first five patients in its ASCENT ASD U.S. Investigational Device Exemption (IDE) pivotal trial. This study, the company’s first in the US, will evaluate the safety and efficacy of the reSept ASD Occluder.

Read more

April 20, 2021

atHeart Medical has commenced operations and is initiating its U.S. IDE trial.

atHeart Medical announced today that it has commenced operations and is initiating its U.S. Investigational Device Exemption (IDE) trial.

Read more

Sigler M, Söderberg B, Schmitt B, Mellmann A, Bernhard J. Carag bioresorbable septal occluder (CBSO): histopathology of experimental implants. EuroIntervention. 2018 Feb 20;13(14):1655-1661 Read more